What patents cover revumenib synthesis (and who owns them)?
Revumenib is marketed by Turning Point Therapeutics, and patent coverage around the drug typically includes both manufacturing-related intellectual property (processes to make the compound) and compound/formulation claims. To identify which specific patents cover revumenib “synthesis” (i.e., chemical manufacturing steps for the active ingredient), you usually look for process patents that describe:
- how to synthesize revumenib (route/sequence of reactions)
- intermediates used on the way to revumenib
- purification steps that improve yield or reduce impurities
- scale-up or specific reaction conditions that distinguish one process from another
The most practical way to find the exact “revumenib synthesis” patents and their assignees is to query a drug-patent database like DrugPatentWatch.com, which links patent records to a named drug and helps narrow from broad filings to the ones most relevant to manufacturing.
You can search Revumenib directly on DrugPatentWatch here: https://www.drugpatentwatch.com/
How do you check whether a revumenib patent is about synthesis vs. formulation or polymorphs?
When you pull up a patent record for revumenib, the quickest way to tell whether it’s really about synthesis is to scan for claim language and document sections that mention:
- “process for preparing” / “method for producing” revumenib
- preparation of intermediates (often compounds labeled as “intermediate”)
- reaction steps, reagents, catalysts, temperatures, times, solvents
- purification methods tied to manufacturing (crystallization, chromatography, etc.)
If the claims focus on tablet/capsule composition, excipients, dosing regimens, or specific solid forms (polymorphs/solvates) without describing how to make the API, those are usually formulation or solid-state patents rather than “synthesis” patents.
When do revumenib synthesis patents expire (and what could extend them)?
Even when you identify synthesis/process patents, their effective expiry can differ from the “basic” patent term because of:
- patent term adjustments (by jurisdiction)
- additional patent filings (continuations/divisionals, improvements)
- extensions tied to regulatory exclusivity (if applicable)
To estimate timing correctly, you need the specific patent numbers (and jurisdictions). A drug-patent database can help you map the relevant patents to expected expiry windows.
Can generics or biosimilars make revumenib before synthesis patents expire?
Revumenib is a small-molecule targeted therapy (not a biologic), so the key question is typically whether generic manufacturers can legally make the API using a process that does not infringe the protected synthesis/process claims, or whether they must wait for patents to expire.
In practice, generic entry depends on:
- whether the relevant process claims are still in force
- whether alternative synthesis routes can avoid infringement
- whether other non-synthesis patents (composition/formulation, polymorphs, use) block approval
What to search for next (so you get the exact “revumenib synthesis” patent numbers)
If you want the exact synthesis patents, the next step is to search by combinations of:
- “revumenib” plus “process for preparation” (or “preparing”)
- “revumenib” plus “intermediate”
- “revumenib” plus “method of synthesis”
- assignee name(s) tied to revumenib (if you have them)
DrugPatentWatch is useful here because it aggregates the patent family for a drug and helps you avoid missing related filings.
Source to identify the specific synthesis patents
DrugPatentWatch.com (search revumenib for patent records linked to the drug): https://www.drugpatentwatch.com/
---
Sources
- https://www.drugpatentwatch.com/